Core Viewpoint - The initial public offering (IPO) application of Bai'ao Saitou (Beijing) Pharmaceutical Technology Co., Ltd. has been approved by the Shanghai Stock Exchange's listing committee, aiming to raise 1.185 billion yuan through the issuance of approximately 99.85 million shares [1] Financial Performance - The company reported revenues of 534 million yuan, 717 million yuan, and 980 million yuan for the years 2022, 2023, and 2024 respectively, indicating a revenue growth of 36.76% in 2024 [1] - The net profit figures for the same years were -600 million yuan, -382 million yuan, and 33.54 million yuan, showing a significant turnaround with a year-on-year growth of 108.76% in net profit for 2024 [1] Research and Development - The company's R&D expenditures over the past three years were 699 million yuan, 474 million yuan, and 324 million yuan, representing 130.96%, 66.17%, and 33.04% of revenue respectively [1] - As of December 31, 2024, the company employed 337 R&D personnel, accounting for 30.78% of its total workforce [1] Use of Proceeds - The funds raised from the IPO will be allocated to the construction of a drug early-stage R&D service platform, antibody drug R&D and evaluation projects, clinical and preclinical R&D projects, and to supplement working capital [1]
百奥赛图首发获上交所上市委会议通过